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Chapter 1
Therapeutic Antibodies: Current State and Future
Trends – Is a Paradigm Change Coming Soon?
Dimiter S. Dimitrov and James D. Marks
Abstract
Antibody-based therapeutics currently enjoy unprecedented success, growth in research and revenues,
and recognition of their potential. It appears that the promise of the ‘‘magic bullet’’ has largely been
realized. There are currently 22 monoclonal antibodies (mAbs) approved by the United States Food and
Drug Administration (FDA) for clinical use and hundreds are in clinical trials for treatment of various
diseases including cancers, immune disorders, and infections. The revenues from the top five therapeutic
antibodies (Rituxan, Remicade, Herceptin, Humira, and Avastin) nearly doubled from $6.4 billion in
2004 to $11.7 billion in 2006. During the last several years major pharmaceutical companies raced to
acquire antibody companies, with a recent example of MedImmune being purchased for $15.6 billion by
AstraZeneca. These therapeutic and business successes reflect the major advances in antibody engineering
which have resulted in the generation of safe, specific, high-affinity, and non-immunogenic antibodies
during the last three decades. Currently, second and third generations of antibodies are under develop-
ment, mostly to improve already existing antibody specificities. However, although the refinement of
already known methodologies is certainly of great importance for potential clinical use, there are no
conceptually new developments in the last decade comparable, for example, to the development of
antibody libraries, phage display, domain antibodies (dAbs), and antibody humanization to name a few.
A fundamental question is then whether there will be another change in the paradigm of research as
happened 1–2 decades ago or the current trend of gradual improvement of already developed methodol-
ogies and therapeutic antibodies will continue. Although any prediction could prove incorrect, it appears
that conceptually new methodologies are needed to overcome the fundamental problems of drug (anti-
body) resistance due to genetic or/and epigenetic alterations in cancer and chronic infections, as well as
problems related to access to targets and complexity of biological systems. If new methodologies are not
developed, it is likely that gradual saturation will occur in the pipeline of conceptually new antibody
therapeutics. In this scenario we will witness an increase in combination of targets and antibodies, and
further attempts to personalize targeted treatments by using appropriate biomarkers as well as to develop
novel scaffolds with properties that are superior to those of the antibodies now in clinical use.
Key words: Antibody therapy, Rituxan, Herceptin, Remicade, Synagis, Humira, Avastin, IgG1,
domain antibodies, antibody-derived scaffold.
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1. Introduction
Antibody therapy has its roots thousands of years ago; early forms
of vaccination against infectious diseases were developed in China
as early as 200 BC. However, the history of true antibody therapy
began about a century ago with the discovery that serum from
animals immunized with toxins, for example, diphtheria toxin or
viruses, is an effective therapeutic against the disease caused by the
same agent in humans. In the 1880s von Behring developed an
antitoxin that did not kill the bacteria, but neutralized the toxin
that the bacteria released into the body. Von Behring was awarded
the first Nobel Prize in Medicine in 1901 for his role in the
discovery and development of a serum therapy for diphtheria.
As he emphasized in his Nobel lecture, the serum therapy would
not be possible without prior work mostly of Loffler (who dis-
covered the diphtheria bacilli) and Roux who reasoned that the
disease (diphtheria) is caused by the toxin and not by the bacteria
(http://nobelprize.org/nobel_prizes/medicine/laureates/1901/
behring-lecture.html). The birth of the therapeutic antibodies
would not have been possible without the paradigm change at
the end of the past century – understanding that microorganisms
and toxins they produce do exist and they can cause diseases. This
new knowledge combined with the development at that time of a
number of new methodologies for the study and manipulation of
microorganisms and better understanding of cell and human
physiology all were critically important for the discovery of the
first antibody-based therapy. It was called serum therapy because
whole serum from the blood of immunized animals was used for
treatment. However, the existence of antibodies was anticipated
and von Behring specifically used the term anti-bodies although
antibodies were not isolated or characterized until decades later.
Following the initial successes in the late 1800s, sera from
humans or animals containing antibodies were widely used for
prophylaxis and therapy of viral and bacterial diseases (1–4).
Serum therapy of most bacterial infections was abandoned in the
1940s after antibiotics became widely available (3). However,
polyclonal antibody preparations are being used for some toxin-
mediated infectious diseases and venomous bites (1). Serum
immunoglobulin is also being used for viral diseases where there
are few treatments available, although immunoglobulin is largely
used for pre- or post-exposure prophylaxis (5–7). Antibody pro-
ducts licensed in the USA for prevention or treatment of viral
diseases include human immunoglobulin for use against hepatitis
A and measles, virus-specific polyclonal human immunoglobulin
against cytomegalovirus, hepatitis B, rabies, respiratory syncytial
virus (RSV), vaccinia, and varicella-zoster, and the humanized
2 Dimitrov and Marks
monoclonal antibody (mAb) Synagis (5) (see also Table 1.1).
Polyclonal immunoglobulin has also been used with various suc-
cess for diseases caused by other human viruses including parvo-
virus B19 (PV B19) (8–11), Lassa virus (12, 13), West Nile virus
(14, 15), some enteroviruses (16, 17), herpes simplex virus (18),
Crimean-Congo hemorrhagic fever virus (CCHFV) (19), Junin
virus (20), SARS-CoV (21, 22), and HIV (23–28), and for treat-
ment of some diseases of the immune system, for example,
for treatment of primary immunodeficiency disorders associated
with defects in humoral immunity (see also GAMMAGARD1 in
Table 1.1).
Although serum polyclonal antibody preparations have been
clinically effective in many cases, problems related to toxicity
including a risk for allergic reactions, lot-to-lot variation, and
uncertain dosing have limited their use (1). In addition, the active
antigen-specific antibodies in a polyclonal preparation typically
represent a relatively small portion of the total antibodies (1%);
the rest of the antibodies are not only ineffective but could be even
toxic or immunogenic. However, until the 1970s it was not
possible to produce large amounts of antibodies with the desired
specificity.
The beginning of the paradigm change for antibodies began
in 1975 with the publication of the seminal article (29) describing
hybridoma technology which can provide unlimited quantities of
mAbs with predefined specificity. In addition, this technology was
not patented and could be used freely. A major limitation of the
hybridoma technology has been the inability to produce human
mAbs. Administration of murine mAbs in humans resulted in
immune responses against the foreign proteins with the genera-
tion of human anti-mouse antibodies (HAMAs). However, the
advent of a number of molecular biology techniques, mostly
recombinant DNA technology, and the increased understanding
of the antibody structure and function led to the development of
chimeric and humanized mAbs. Finally, phage-display techniques
and other techniques based on the progress of molecular biology,
including the generation of transgenic animals, allowed the devel-
opment of fully human antibodies; these methodologies have
been extensively reviewed (30–58). This completed the paradigm
change which occurred mostly during a period of 2–3 decades
beginning in the 1970s and ending in the 1990s. We are witnes-
sing the fruits of this paradigm change which have resulted in a
number of useful therapeutic antibodies approved for clinical use
during the last decade.
However, during the last decade the basic concepts and meth-
odologies for antibody generation have not changed significantly
but have been applied to numerous new targets. Do we expect
another paradigm change in the near future? Are the currently
used methodologies and antibodies developed based on these
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methodologies reaching their limit? Is it possible to produce
conceptually new antibodies that are able to resolve long-standing
problems including efficient oral delivery, penetration into solid
tumors, and low cost of production which are the major draw-
backs of antibodies in comparison to small molecules? Or perhaps,
increasing the complexity by making multifunctional antibody-
based drugs including nanoparticle conjugates with antibodies in
various formats could result in novel therapeutics with unique and
useful properties. Here we briefly overview the current state of
antibody therapeutics and try to answer these and other questions
related to the directions which this field may follow in the future.
More indepth analysis and details can be found in the excellent
reviews (56, 59–61).
2. Lessons from
mAbs Currently
in Clinical Use
A total of 22 mAbs are currently approved by the US FDA for
clinical use; almost all of them are for treatment of cancer and
diseases related to the immune system (Tables 1.1 and 1.2). (In
April 2008 FDA approved Cimzia for treatment of Crohn’s dis-
ease) Many more mAbs are in clinical trials (1373 entries for
ongoing or completed clinical trials were retrieved from (http://
www. clinicaltrials.gov) by searching with ‘‘therapy and mAbs’’ as
of March 2008). During the last decade and especially in the last
years the number of clinical trials with therapeutic antibodies has
increased dramatically (Table 1.3 presents a snapshot of clinical
trials up to the year 2000). However, this increase has been largely
due to an increase in the number of targets and indications for the
same antibodies especially in combination with other therapeutics.
The number of targets and corresponding antibodies in preclinical
development and in the discovery phase has also increased signifi-
cantly during the past decade (see, e.g., the latest and largest meet-
ing on Molecular Targets and Cancer Therapeutics, October
22–26, 2007, San Francisco, http://www.aacr.org, where the
proportion of presentations related to mAbs has increased signifi-
cantly compared to previous years). Therefore, currently research
and development of mAbs as potential therapeutics is growing.
The mAb market ushered into a ‘‘take-off’’ phase by the 1997
launch of Rituxan (rituximab) (marketed as MabThera in Europe)
for non-Hodgkin’s lymphoma (NHL). Rituxan represented the
first mAb product to succeed commercially in a high-revenue/
high-growth market (oncology) and to provide significant
enhancements in the efficacy of treatment versus existing non-
mAb therapies. As a result, Rituxan rapidly became established as
the gold-standard therapy for NHL and the first-launched mAb
10 Dimitrov and Marks
Table 1.2
Monoclonal antibodies approved by the USA FDA for clinical use and their
targets as of March 8, 2008 (modified from http://en.wikipedia.org/wiki/
Monoclonal_antibody_therapy see also the excellent review by Carter (56) where
all monoclonal antibodies approved by the US FDA from 1986 to 2004 are listed with
their targets, antibody formats, affinities, proposed mechanisms of action, and
approved indications as well as the company). Note the convention for antibody
names – ending with momab for murine antibodies, ximab for chimeric, zumab for
humanized, and mumab for fully human antibodies. The antibodies are arranged
alphabetically according to their names (in contrast to Table 1.1 where the order is
based on their brand names)
Antibody Brand name
Approval
date Target Approved treatment(s)
Abciximab ReoPro 1994 gpIIb-gpIIIa,
v3
Cardiovascular disease
Adalimumab Humira 2002 TNF Inflammatory diseases (mostly
autoimmune disorders)
Alemtuzumab Campath 2001 CD52 Chronic lymphocytic leukemia
Basiliximab Simulect 1998 IL-2 receptor  Transplant rejection
Bevacizumab Avastin 2004 Vascular
endothelial
growth factor
Colorectal cancer
Cetuximab Erbitux 2004 Epidermal
growth factor
receptor
Colorectal cancer
Daclizumab Zenapax 1997 IL-2 receptor  Transplant rejection
Eculizumab Soliris 2007 Complement
system protein
C5
Inflammatory diseases including
paroxysmal nocturnal
hemoglobinuria
Efalizumab Raptiva 2002 CD11a Inflammatory diseases (psoriasis)
Gemtuzumab
ozogamicin
Mylotarg 2000 CD33 Acute myelogenous leukemia
(AML) (with calicheamicin)
Ibritumomab
tiuxetan
Zevalin 2002 CD20 NHL (with yttrium-90 or
indium-111)
Infliximab Remicade 1998 Inhibition of
TNF
signalling
Inflammatory diseases (mostly
autoimmune disorders)
(continued)
Therapeutic Antibodies 11
product which went on to achieve blockbuster status (revenues
above $1 billion per year).
Several mAbs launched in subsequent years also became
blockbusters: Herceptin (1998), Remicade (1998), Synagis
(1998), Humira (2002), and Avastin (2004); the six mAbs gener-
ated total revenues of more than $12 billion in 2006 (Table 1.4).
The other 15 mAbs generated about 10% (about $1 billion) of the
total revenues from mAbs for 2006. The revenues from blockbuster
mAbs have been steadily increasing typically with double-digit
percentage growth each year (Table 1.4) and are projected to
continue to increase. They are mostly products from four estab-
lished companies at the top end of the market: Genentech, Roche,
Abbott, and Johnson & Johnson each of which generated mAb
revenues in excess of $2 billion in 2006. MedImmune (now part of
AstraZeneca) follows closely. An additional tier of four companies,
Biogen Idec, Amgen, Novartis, and UCB Pharma, is also evident
with each forecast to record absolute annual mAb sales growth in
Table 1.2 (continued)
Antibody Brand name
Approval
date Target Approved treatment(s)
Muromonab-
CD3
Orthoclone
OKT3
1986 T-cell CD3
receptor
Transplant rejection
Natalizumab Tysabri 2006 T-cell VLA4
receptor
Inflammatory diseases (mainly
autoimmune-related multiple
sclerosis therapy)
Omalizumab Xolair 2004 Immunoglobulin
E (IgE)
Inflammatory diseases (mainly
allergy-related asthma therapy)
Palivizumab Synagis 1998 An epitope of the
F protein of
RSV
Prevention of RSV infection
Panitumumab Vectibix 2006 Epidermal
growth factor
receptor
Colorectal cancer
Ranibizumab Lucentis 2006 Vascular
endothelial
growth factor
Macular degeneration
Rituximab Rituxan,
MabThera
1997 CD20 NHL
Tositumomab Bexxar 2003 CD20 NHL
Trastuzumab Herceptin 1998 ErbB2 Breast cancer
12 Dimitrov and Marks
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excess of $1 billion over the period 2006–2012. The dramatic
increase in revenues for the last decade and the forecast for even
larger revenues in the next decade has prompted the major
pharmaceutical companies to acquire a number of antibody
companies in an equally dramatic race during the last several
years (Table 1.5) and/or create their own antibody or biologi-
cals departments. Today all major pharmaceutical companies and
a still increasing number of smaller biotech companies identify
and develop novel antibody-based therapeutics. This completes
the paradigm change resulting in the conversion of mAbs from
promising therapeutics, being developed mostly by biotech
companies, into ‘‘regular’’ therapeutics about as important as,
or perhaps in some cases more important than, small-molecule
drugs. Thus most of the new antibody therapeutics or improve-
ments in existing ones which could be clinically used are
expected to be developed at large companies in their biologicals
departments.
Currently about 200 different antibody-based candidate
therapeutics are in clinical trials targeting about 70 different
molecules (see, e.g., www.phrma.org where 418 biomedicines
in clinical trials, including mAbs, are listed for 2006). At least
1–3 different antibodies are being developed at different com-
panies for each relevant therapeutic target, with a notable excep-
tion, the IGF-IR, which is being targeted by more than ten
different mAbs (62). Second- and third-generation mAbs are
being developed against already validated targets. For example,
based on Synagis, an antibody (motavizumab (MEDI-524;
NuMax)) was developed with much higher affinity to the F
protein of the RSV (63); it is expected to be approved by FDA
Table 1.4
Revenues from blockbuster therapeutic antibodies (in billion
US$) for years 2004, 2005, and 2006
Antibody Disease 2004 2005 2006
Rituxan Cancer, arthritis 1.6 1.8 2.1
Remicade Arthritis 2.9 3.6 4.4
Herceptin Cancer 0.5 0.7 1.3
Synagis Infection 0.9 1.1 1.1
Humira Arthritis 0.8 1.4 2.0
Avastin Cancer 0.6 1.2 1.9
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this year and ultimately replace Synagis for which the patent
expires in 2015. The improvement of already existing antibodies
also includes an increase (to a certain extent) in their binding to
Fc receptors for enhancement of ADCC and half-life, selection
of appropriate frameworks to increase stability and yield,
decrease of immunogenicity by using in silico and in vitro meth-
ods, and conjugation to small molecules and various fusion
proteins to enhance cytotoxicity. A major lesson from the cur-
rent state of antibody-based therapeutics is that gradual
improvement in the properties of existing antibodies and identi-
fication of novel antibodies and novel targets is likely to continue
in the foreseeable future. This is likely to be a major driving force
of the field until saturation is reached presumably in the next
decade or two, and various combinations of antibodies and other
drugs may dominate unless a major change in the current para-
digm occurs.
Table 1.5
Antibody companies acquired by large companies
Company Large Company
Acquisition cost
(billion US$) Year
GlycArt Roche 0.2 2005
Bioren Pfizer Undisclosed 2005
Abgenix Amgen 2.2 2006
CAT AstraZeneca 1.3 2006
Zenyth CSL 0.1 2006
Abmaxis Merck 0.08 2006
NeuTec Novartis 0.6 2006
Rinat Pfizer 0.5 2006
Domantis GSK 0.5 2006
Morphotek Eisai 0.3 2007
THP Roche 0.06 2007
Tanox Genentech 0.9 2007
MedImmune AstraZeneca 15.6 2007
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3. Beyond
Antibodies as an
Alternative to a
Paradigm Change
The rapid expansion in mAb revenues in the next decade is likely
to be driven by a number of key individual products recording
peak sales growth and the launch of new products. Furthermore, a
number of key mAb products are the subject of horizontal indica-
tion broadening strategies. This trend is expected to further
enhance revenue growth. The most notable example of this strat-
egy is Genentech and Roche’s Avastin (bevacizumab). Given its
broad-spectrum mode of action (it targets angiogenesis) it can be
used across a wide range of tumor types. Although by no means
representing an end of mAb market sales expansion, revenue
growth may begin to slow by 2012. Competition between rival
mAb products will begin to slow sales growth for some franchises
(Humira sales growth at the expense of Remicade for example),
while some second-generation product launches (such as Med-
Immune’s Numax (motavizumab, MEDI-524) which is expected
to be launched this (2008) year for the 2008/2009 RSV season)
will cannibalize sales of first-generation mAb products (MedIm-
mune’s Synagis). Ultimately, organic revenue expansion in any
market is finite and this will prove the case in the mAb segment,
despite the indication broadening opportunities available for
many brands. However, revenues from mAbs will still grow faster
than those from small molecules which face an unattractive com-
bination of high exposure to generic competition, no major focus
on areas of highest unmet need, and little access to novel target
space – all conspiring to make this product set the slowest growing
to 2012.
The question then is whether a new paradigm change could
trigger a new dramatic expansion of some novel, still unknown,
types of therapeutics. We do not know the answer to this question
and surprises are always possible but currently there are no indica-
tions that another paradigm change in the discovery of biological
therapeutics is coming anytime soon. It rather appears that there
will be gradual improvements in existing antibodies and identifi-
cation of antibodies to novel targets using currently available
methodologies. However, one area where one could expect con-
ceptually novel antibody-based candidate therapeutics, although
within the current paradigm, is going beyond traditional antibody
structures (see, e.g., the latest (2008) meeting Beyond Antibodies
http://www.ibclifesciences.com/beyond/overview.xml)
Currently, almost all FDA-approved therapeutic antibodies
(Tables 1.1, 1.2, and 1.3) (except ReoPro, Lucentis, and Cimzia
which are Fabs) and the vast majority of those in clinical trials are
full-size antibodies mostly in IgG1 format of about 150-kDa size.
A fundamental problem for such large molecules is their poor
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penetration into tissues (e.g., solid tumors) and poor or absent
binding to regions on the surface of some molecules (e.g., on the
HIV envelope glycoprotein) which are accessible by molecules of
smaller size. Therefore, a large amount of work especially during
the last decade has been aimed at developing novel scaffolds of
much smaller size and higher stability (see, e.g., a recent review
(54)). Such scaffolds are based on various human and non-human
molecules of high stability and could be divided into two major
groups for the purposes of this review – antibody-derived and
others. Here we will briefly discuss antibody-derived scaffolds,
specifically those derived from antibody domains, as an example
of potentially useful candidate therapeutics; an excellent recent
review describes the second group (54).
The first two domain antibodies (dAbs) entered clinical trials
(phase I) last year. One of them, ALX-0081, is a camelid dAb
targeting the von Willebrand factor (vWF). (Because of their small
size the camelid dAbs are also termed nanobodies by the com-
pany, Ablynx, which develops them). The neutralization of the
vWF could reduce the risk of thrombosis in patients with acute
coronary syndrome (ACS) and thrombotic thrombocytopenic
purpura (TTP). Ablynx reported the results from its phase I
study in December 2007 (http://www.ablynx.com). The other
dAb, ART621, is a human protein targeting TNF. In preclinical
studies, it demonstrated potency levels at least equivalent to a
market-leading anti-TNF drug in an animal model of rheumatoid
arthritis. The phase I clinical trial which showed that the drug was
well-tolerated in healthy volunteers was successfully completed in
November 2007. In March 2008, the biotechnology company
Arana Therapeutics Limited (http://www.arana.com) which
develops this antibody announced that it has commenced recruit-
ment for a phase II trial in psoriasis. If successful, the company
plans to initiate a phase III trial in 2009. This antibody was
licensed from Domantis (http://www.domantis.com) which is
now a wholly owned subsidiary of GSK. Many additional dAbs
are in early stages of development.
What are the features of the dAbs which make them attrac-
tive as candidate therapeutics? Firstly, their size (12–15 kDa) is
about an order of magnitude smaller than the size of an IgG1
(about 150 kDa). The small size leads to relatively good pene-
tration into tissues and the ability to bind into cavities or active
sites of protein targets which may not be accessible to full-size
antibodies. This could be particularly important for the develop-
ment of therapeutics against rapidly mutating viruses, for exam-
ple, HIV. Because these viruses have evolved in humans to escape
naturally occurring antibodies of large size, some of their surface
regions which are critical for the viral life cycle may be vulnerable
to targeting by molecules of smaller size including dAbs. Sec-
ondly, dAbs may be more stable than full-size antibodies in the
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circulation and can be relatively easily engineered to further
increase their stability. For example, some dAbs with increased
stability could be taken orally or delivered via the pulmonary
route or may even penetrate the blood–brain barrier, and retain
activity even after being subjected to harsh conditions, such as
freeze-drying or heat denaturation. In addition, dAbs are typi-
cally monomeric, of high solubility, and do not significantly
aggregate or can be engineered to reduce aggregation. Their
half-life in the circulation can be relatively easily adjusted from
minutes or hours to weeks. In contrast to conventional antibo-
dies, dAbs are well expressed in bacterial, yeast, and mammalian
cell systems. Finally, the small size of dAbs allows for higher
molar quantities per gram of product, which should provide a
significant increase in potency per dose and reduction in overall
manufacturing cost (http://www.domantis.com).
Research on novel antibody-derived scaffold continues. We
have identified a VH-based scaffold which is stable and highly
soluble (64, 65). It was used for the construction of a large-size
(20-billion clone) dAb phage library by grafting CDR3s and
CDR2s from five of our other Fab libraries and randomly muta-
genizing CDR1. Panning of this library with an HIV Env com-
plexed with CD4 resulted in the identification of a very potent
broadly cross-reactive dAb against HIV, m36, which neutralized
primary HIV isolates from different clades with IC50s and IC90s
in the low mg/ml range. One of the authors (DSD) has proposed
to use engineered antibody constant domains (CH2 of IgG, IgA,
and IgD, and CH3 of IgE and IgM) as scaffolds for construction
of libraries. Because of their small size and the domains role in
antibody effector functions, these have been termed nanoanti-
bodies, the smallest fragments that could be engineered to exhi-
bit simultaneously antigen-binding and effector functions.
Several large libraries (up to 50-billion clones) were constructed
and antigen-specific binders successfully identified (Xiao, Vu,
Dimitrov et al., in preparation). It is possible that these and
other novel scaffolds under development could provide new
opportunities for identification of potentially useful thera-
peutics.
4. Conclusions
The rapid progress made in the last few decades toward the
development of potent therapeutic antibodies mostly against can-
cer and immune diseases raises a number of questions for the
future directions of this field. A key question is whether there
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are any indications of a paradigm change that could lead to radi-
cally different therapeutics as occurred 2–3 decades ago and which
resulted in an explosion of antibody therapeutics approved for
clinical use during the last decade. If history provides an answer
and such a paradigm shift occurs, it will probably take decades
before we witness the fruition of such a shift in terms of new
licensed antibody therapeutics. Meanwhile, gradual improve-
ments in the characteristics of existing antibodies, discovery of
novel antibodies and novel targets, combining antibodies, con-
jugating them with drugs, nanoparticles, and other reagents, and
going beyond antibodies by developing novel antibody-based
scaffolds with superior properties to those already in use will be
major areas of research and development in the coming decades. A
decade from now it is likely that we will see many antibody-based
therapeutics based on different scaffolds than the IgG1 approved
for clinical use and hundreds more in preclinical and clinical
development.
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